This study is a phase ll and the purpose of this study is to determine if giving TSR-022 and TSR-042 will shrink the tumor in participants with hepatocellular carcinoma (liver cancer).

This is an observational study of individuals with suspected or confirmed gastrointestinal cancer. The purpose of this study is to look at these individuals to understand gastrointestinal cancer and develop new and better ways to treat this disease.

This study is being done to understand if the way rectal tumors respond to standard of care treatment can be associated with varying levels of ctDNA. The goal is to measure the levels of ctDNA change during and see if there's any levels after the treatment.

The purpose of the study is to learn more about whether adding onvansertib to standard treatment of FOLFIRI (Folinic Acid, fluorouracil, and irinotecan) or FOLFOX (Fluoropyrimidine and oxaliplatin) and bevacizumab will improve results in untreated metastatic colorectal cancer with a KRAS or NRAS mutation.If you decide to take part in this study, and are deemed eligible to participate, you will get randomized to one of 6 arms which are as follows:The study drug at a lower dose level + FOLFOX + bevacizumabThe study drug at a lower dose level + FOLFIRI + bevacizumabThe study drug at a higher dose level + FOLFOX + bevacizumabThe study drug at a higher dose level + FOLFIRI + bevacizumabFOLFOX + BevacizumabFOLFIRI + Bevacizumab You will have an equal chance of being placed in each arm.